A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects with Type 2 Diabetes Mellitus

  • STATUS
    Not Recruiting
Updated on 21 April 2022

Summary

A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects with Type 2 Diabetes Mellitus

Description

This study is to support the development of MK-1293, a proposed follow-on insulin glargine, using Lantus™ (insulin glargine, Sanofi-aventis Pharmaceuticals, Frankfurt, Germany) as the comparator medicinal product. This study will assess the safety and efficacy of MK-1293 compared to Lantus™.

Lead Principal Investigator: Dr. Priscilla Hollander

Baylor Endocrine Center
3600 Gaston Ave.
Dallas, TX 75246

IRB Number: 013-145

Details
Condition Diabetes Mellitus, Type 2, Diabetes Mellitus Types I and II
Clinical Study IdentifierTX138055
Last Modified on21 April 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note